- Conditions
- Congenital Hyperinsulinism
- Interventions
- dasiglucagon
- Drug
- Lead sponsor
- Zealand Pharma
- Industry
- Eligibility
- 5 Weeks to 13 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 3
- States / cities
- Aurora, Colorado • Philadelphia, Pennsylvania • Fort Worth, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–9
of 9
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Congenital Hyperinsulinism
- Interventions
- dasiglucagon, Placebo
- Drug
- Lead sponsor
- Zealand Pharma
- Industry
- Eligibility
- 7 Days to 364 Days
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 2
- States / cities
- Philadelphia, Pennsylvania • Fort Worth, Texas
- Conditions
- Hypoglycemia, Type 1 Diabetes
- Interventions
- Dasiglucagon
- Drug
- Lead sponsor
- Zealand Pharma
- Industry
- Eligibility
- Up to 5 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia • Fort Worth, Texas
- Conditions
- Hypoglycemia, Diabetes Mellitus, Type 1
- Interventions
- Dasiglucagon, Placebo
- Drug
- Lead sponsor
- Zealand Pharma
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 3
- States / cities
- Chula Vista, California • Escondido, California • Renton, Washington
- Conditions
- Congenital Hyperinsulinism
- Interventions
- Dasiglucagon, Standard of Care
- Drug · Other
- Lead sponsor
- Zealand Pharma
- Industry
- Eligibility
- 3 Months to 12 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 3
- States / cities
- Aurora, Colorado • Philadelphia, Pennsylvania • Fort Worth, Texas
- Conditions
- Hypoglycemia
- Interventions
- dasiglucagon, placebo, GlucaGen HypoKit
- Drug
- Lead sponsor
- Zealand Pharma
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 3
- States / cities
- Escondido, California • New Haven, Connecticut • Indianapolis, Indiana
- Conditions
- Hypoglycemia, Diabetes Mellitus, Type 1
- Interventions
- Dasiglucagon, GlucaGen, Placebo
- Drug
- Lead sponsor
- Zealand Pharma
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 170 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Chula Vista, California
- Conditions
- Hypoglycemia, Diabetes Mellitus, Type 1
- Interventions
- dasiglucagon, GlucaGen
- Drug
- Lead sponsor
- Zealand Pharma
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 112 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 2
- States / cities
- Orlando, Florida • Meridian, Idaho
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Insulin Lispro, ZP4207 (dasiglucagon), Glucagon, iPhone-based bionic pancreas, iLet-based bionic pancreas
- Drug · Device
- Lead sponsor
- Zealand Pharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts